Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study
Main findingResult — go to the resultAdjusted odds ratio 5.8 95% CI 1.7–19.3Authors' conclusion
In fasting patients, GLP-1 agonist therapy was associated with an increased incidence of residual gastric contents, potentially posing an additional risk of periprocedural pulmonary aspiration.
Study context
- Population
- Fasting patients undergoing esophagogastroduodenoscopy (EGD) under anaesthesia care, 2019–2023; excluding emergent procedures without fasting, combined EGD/colonoscopy, known gastroparesis or previous gastric surgery
- Exposure
- GLP vs Control
- GLPn = 90 procedures
- Controln = 102 proceduresreference
- Outcome
- Endoscopically visible residual gastric contents after preprocedural fasting
Methodological detailsretrospective, single-centre, confounder-adjusted generalized linear mixed effect model
- Retrospective
- Single-centre
- Confounder-adjusted generalized linear mixed effect model
Main finding
As reported in the abstract
Adjusted odds ratio
5.8
95% CI 1.7–19.3
P = 0.004
Events by group
GLP vs Control
aOR 5.8 (95% CI 1.7–19.3); P = 0.004
Observational data: associations, not effects.
Safety
Events
| Outcome | GLP | Control |
|---|---|---|
| Emergent endotracheal intubation | 5 | 1 |
| Pulmonary aspiration | 1 | 0 |
Original publication
Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study. Can J Anaesth. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →